NZ592432A - Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1) - Google Patents

Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)

Info

Publication number
NZ592432A
NZ592432A NZ592432A NZ59243209A NZ592432A NZ 592432 A NZ592432 A NZ 592432A NZ 592432 A NZ592432 A NZ 592432A NZ 59243209 A NZ59243209 A NZ 59243209A NZ 592432 A NZ592432 A NZ 592432A
Authority
NZ
New Zealand
Prior art keywords
kaag1
antigen
antibodies
biological activity
specifically block
Prior art date
Application number
NZ592432A
Other languages
English (en)
Inventor
Gilles Bernard Tremblay
Mario Filion
Traian Sulea
Original Assignee
Alethia Biotherapeutics Inc
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alethia Biotherapeutics Inc, Ca Nat Research Council filed Critical Alethia Biotherapeutics Inc
Publication of NZ592432A publication Critical patent/NZ592432A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ592432A 2008-11-03 2009-11-03 Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1) NZ592432A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19318408P 2008-11-03 2008-11-03
US21366609P 2009-06-30 2009-06-30
PCT/CA2009/001586 WO2010060186A1 (en) 2008-11-03 2009-11-03 Antibodies that specifically block the biological activity of a tumor antigen

Publications (1)

Publication Number Publication Date
NZ592432A true NZ592432A (en) 2013-01-25

Family

ID=42225161

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ592432A NZ592432A (en) 2008-11-03 2009-11-03 Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)

Country Status (13)

Country Link
US (3) US9855291B2 (enExample)
EP (2) EP2362908A4 (enExample)
JP (2) JP5781932B2 (enExample)
KR (1) KR20110084280A (enExample)
CN (2) CN102245773B (enExample)
AU (1) AU2009321508B2 (enExample)
BR (1) BRPI0921805A2 (enExample)
CA (2) CA2740900C (enExample)
IL (1) IL212637A0 (enExample)
MX (1) MX336869B (enExample)
NZ (1) NZ592432A (enExample)
WO (1) WO2010060186A1 (enExample)
ZA (1) ZA201104110B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120128661A1 (en) * 2006-06-23 2012-05-24 Alethia Biotherapeutics Inc. Polynucleotide and polypeptide sequences involved in cancer
EP2502628B1 (en) * 2006-06-23 2016-12-14 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
WO2010060186A1 (en) 2008-11-03 2010-06-03 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
WO2012125551A1 (en) 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
DK3173427T3 (da) * 2011-03-31 2019-08-05 Adc Therapeutics Sa Antistoffer mod nyre-associeret antigen 1 og antigen-bindende fragmenter deraf
HRP20190946T1 (hr) * 2012-01-09 2019-07-26 Adc Therapeutics Sa Sredstva za liječenje trostruko negativnog raka dojke
EP3578569A1 (en) * 2012-02-06 2019-12-11 Inhibrx, Inc. Cd47 antibodies and methods of use thereof
EP2825195A4 (en) 2012-03-12 2015-10-07 Advaxis Inc INHIBITION OF SUPPRESSOR CELL FUNCTION AFTER TREATMENT WITH A LISTERIAL VACCINE
AR090903A1 (es) * 2012-05-01 2014-12-17 Genentech Inc Anticuerpos e inmunoconjugados anti-pmel17
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
MX2015008117A (es) * 2012-12-21 2016-03-31 Amplimmune Inc Anticuerpos anti-h7cr.
CN105209616A (zh) 2013-03-14 2015-12-30 雅培制药有限公司 用于改进的抗体检测的hcv ns3重组抗原及其突变体
WO2014143343A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv core lipid binding domain monoclonal antibodies
WO2014158272A1 (en) 2013-03-14 2014-10-02 Abbott Laboratories Hcv antigen-antibody combination assay and methods and compositions for use therein
WO2015031645A1 (en) * 2013-08-28 2015-03-05 Washington University Monoclonal antibodies to human 14-3-3 epsilon and human 14-3-3 epsilon sv
EP3149038B1 (en) * 2014-06-02 2019-08-21 Institut National de la Sante et de la Recherche Medicale (INSERM) Anti-neurotensin antibodies and uses thereof
EP3273994B1 (en) 2015-03-27 2021-12-01 University of Southern California Car t-cell therapy directed to lhr for the treatment of solid tumors
CN107847601A (zh) 2015-06-04 2018-03-27 南加利福尼亚大学 Lym‑1和lym‑2靶向的car细胞免疫疗法
EP3402520A4 (en) * 2016-01-14 2019-01-02 BPS Bioscience, Inc. Anti-pd-1 antibodies and uses thereof
CA3029003A1 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
CN111257482B (zh) * 2018-11-30 2021-11-09 中国科学院大连化学物理研究所 一种细胞内mtdh结合代谢物的鉴定方法
AU2020221324A1 (en) 2019-02-15 2021-09-02 University Of Southern California Lym-1 and Lym-2 antibody compositions and improved CAR constructs
TW202112812A (zh) * 2019-05-24 2021-04-01 香港商安立璽榮生醫(香港)有限公司 Csf1r抗體、il10融合蛋白及其用途
GB201917819D0 (en) * 2019-12-05 2020-01-22 Nordic Bioscience As A neo-epitope specific assay measuring protease mediated degradation of type iv collagen
WO2024044722A1 (en) * 2022-08-24 2024-02-29 City Of Hope Drip-antibodies and use thereof
CN115806614A (zh) * 2022-10-31 2023-03-17 江汉大学 一种Fam50b蛋白多克隆抗体及其制备方法与应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) * 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
DK365785A (da) 1984-09-17 1986-03-18 Hoffmann La Roche Metalcomplexer
US5075447A (en) 1984-09-17 1991-12-24 Hoffmann-La Roche Inc. Ruthenium complexes useful as carriers for immunologically active materials
GB8601646D0 (en) 1986-01-23 1986-02-26 Davidson R S Binding assay & reagent
US5585279A (en) 1986-01-23 1996-12-17 Davidson; Robert S. Time-resolved luminescence binding assays using a fluorescent transition metal label other than ruthenium
US6018030A (en) 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
ES2093090T3 (es) 1989-12-28 1996-12-16 Upjohn Co Compuestos sustituidos diaromaticos anti-sida.
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5708022A (en) 1994-10-28 1998-01-13 Procept, Inc. Method for inhibiting immune response
WO1996013510A1 (en) 1994-10-28 1996-05-09 Procept, Inc. Ruthenium complexes and their use as immunosuppressive agents
US5712127A (en) 1996-04-29 1998-01-27 Genescape Inc. Subtractive amplification
US5831003A (en) 1996-06-28 1998-11-03 Bayer Corporation Peptides which bind to prothrombin and thrombin
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
EP0991777A1 (en) 1997-06-18 2000-04-12 Ulrich J. Krull Nucleic acid biosensor diagnostics
AU1824899A (en) 1997-12-15 1999-07-05 Joseph R Lakowicz Method and composition for characterizing a sample containing a sample lipid andan assay kit
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US6472367B1 (en) 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
ATE380865T1 (de) 1998-05-13 2007-12-15 Domantis Ltd Phagen-display-selektionssystem für korrekt gefaltete proteine
WO1999058546A1 (en) 1998-05-13 1999-11-18 Ludwig Institute For Cancer Research Tumor associated antigen encoded by the reverse strand of a new ubiquitously expressed gene
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US7521197B2 (en) 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
US20020106678A1 (en) 1998-06-30 2002-08-08 Robishaw Janet D. cDNA clones encoding human G protein gamma subunits
JP2002519428A (ja) 1998-07-02 2002-07-02 メルク エンド カムパニー インコーポレーテッド プレニル−タンパク質トランスフェラーゼの阻害剤
US6288221B1 (en) 1998-08-20 2001-09-11 Duke University Methods of synthesis of halogen base-modified oligonucleotides and subsequent labeling with a metal-catalyzed reaction
US6806089B1 (en) 1998-09-08 2004-10-19 University Of Maryland, Baltimore Low frequency modulation sensors using nanosecond fluorophores
WO2000014515A1 (en) 1998-09-08 2000-03-16 University Of Maryland At Baltimore Low frequency modulation sensors using nanosecond fluorophores
AU1223400A (en) 1998-10-22 2000-05-08 Phillip B. B. Moheno Novel pterin antineoplastic agents
AU762440B2 (en) 1998-10-29 2003-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
IL145290A0 (en) 1999-03-19 2002-06-30 Anormed Inc Pharmaceutical compositions comprising complexes
US6872519B1 (en) 1999-04-27 2005-03-29 Mirus Bio Corporation In vitro process for selecting phage resistant to blood inactivation
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
NZ517828A (en) 1999-09-17 2003-10-31 Millennium Pharm Inc Inhibitors having activity against mammalian factor Xa
WO2001046209A1 (en) 1999-12-20 2001-06-28 Fluorrx, Inc. Fluorescent probes
US20030219806A1 (en) 2000-02-22 2003-11-27 Millennium Pharmaceuticals, Inc. Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor
US7585839B2 (en) 2000-02-23 2009-09-08 Zealand Pharma A/S Medical uses of intercellular communication facilitating compounds
US20030215860A1 (en) 2000-02-29 2003-11-20 Millennium Pharmaceuticals, Inc. Novel 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 molecules and uses therefor
AU4592601A (en) 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7834146B2 (en) 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
AU2001269836A1 (en) 2000-06-16 2002-01-02 Incyte Genomics, Inc. Proteases
WO2002006339A2 (en) 2000-07-03 2002-01-24 Curagen Corporation Proteins and nucleic acids encoding same
US20050053930A1 (en) 2000-07-18 2005-03-10 David Anderson Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US6783969B1 (en) 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
US7030236B2 (en) 2001-03-09 2006-04-18 Mona Savitri Jhaveri Antisense oligonucleotides tarageting folate receptor alpha, and the use thereof
US20030087250A1 (en) 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US20030065157A1 (en) 2001-04-04 2003-04-03 Lasek Amy W. Genes expressed in lung cancer
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
AU2002309583A1 (en) 2001-04-18 2002-11-05 Protein Desing Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
ATE389022T1 (de) 2001-05-07 2008-03-15 Ca Nat Research Council Verstärkte herstellung rekombinanter proteine mittels transienter transfektion von in suspension wachsenden säugerzellen
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
JP2005508144A (ja) 2001-06-18 2005-03-31 イオス バイオテクノロジー，インコーポレイティド 卵巣癌の診断方法、卵巣癌のモジュレーターをスクリーニングする組成物及び方法
US20040053824A1 (en) 2001-06-29 2004-03-18 Tang Y Tom Extracellular matrix and cell adhesion molecules
US20030099974A1 (en) 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
JP4328202B2 (ja) 2001-08-31 2009-09-09 ビーティージー・インターナショナル・リミテッド 抗癌シクロペンタ［ｇ］キナゾリン化合物
EP1420809B1 (en) 2001-08-31 2011-09-28 BTG International Limited Use of cyclopenta[g]quinazoline derivatives for treating cancer
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
NZ533158A (en) 2001-11-19 2006-09-29 Elan Pharm Inc 3,4-Disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines and piperazines
AU2002351194A1 (en) 2001-11-30 2003-06-17 Incyte Genomics, Inc. Cell adhesion and extracellular matrix proteins
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
JP2005525096A (ja) 2002-01-09 2005-08-25 ユニバーシティ オブ ローザンヌ Ｊｎｋシグナル伝達経路の細胞浸透性ペプチドインヒビター
ATE371680T1 (de) 2002-01-16 2007-09-15 Biocompatibles Uk Ltd Polymerkonjugate
CA2474723A1 (en) 2002-01-28 2003-08-07 Keraplast Technologies, Ltd. Bioactive keratin peptides
US6962910B2 (en) 2002-02-01 2005-11-08 Virginia Tech Intellectual Properties, Inc. Supramolecular complexes as photoactivated DNA cleavage agents
AU2003225573A1 (en) 2002-02-13 2003-09-04 The Government Of The United States Of America As Represented By The Secretary, Department Of He Identification of ovarian cancer tumor markers and therapeutic targets
DE10206616A1 (de) 2002-02-15 2003-09-04 Qiagen Gmbh Verfahren zur Reduktion der Background-Kontamination nach Markierungsreaktionen
EP1490101A4 (en) 2002-03-05 2006-09-20 Univ Texas METHODS OF IMPROVING INDUCTION OF IMMUNE RESPONSE INVOLVING MDA-7
US20040101874A1 (en) 2002-04-12 2004-05-27 Mitokor Inc. Targets for therapeutic intervention identified in the mitochondrial proteome
PL375064A1 (en) 2002-05-20 2005-11-14 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
AU2003295328A1 (en) 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1422242A1 (en) 2002-11-22 2004-05-26 Emory University Plastic and elastic protein copolymers
KR20050115231A (ko) 2003-02-10 2005-12-07 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 포유동물 세포의 조절
WO2004087874A2 (en) 2003-03-28 2004-10-14 Nuvelo, Inc. Novel nucleic acids and polypeptides
AU2004240765B2 (en) 2003-05-20 2009-03-19 Cellpep Sa Modified antiviral peptides with increased activity and cell membrane affinity
WO2004104197A1 (en) 2003-05-21 2004-12-02 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r1 and uses thereof in the treatment of cancer
US20050008649A1 (en) * 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
US20070027075A1 (en) 2003-06-09 2007-02-01 Smithrud David B Compositions and methods for targeted drug delivery
US20060078941A1 (en) 2003-06-09 2006-04-13 Santin Alessandro D Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
WO2006003352A1 (en) 2004-07-06 2006-01-12 Warwick Effect Polymers Limited Living radical polymerization initiator comprising a functional group capable of reacting with polyeptides or the like, comb polymer obtained therewith, polypeptide conjugates and drugs obtained therefrom
GB0318096D0 (en) 2003-08-01 2003-09-03 Queen Mary & Westfield College Vaccine
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
US20070178458A1 (en) 2003-09-05 2007-08-02 O'brien Philippa Methods of diagnosis and prognosis of ovarian cancer II
US20050147621A1 (en) 2003-10-10 2005-07-07 Higgins Darren E. Use of bacterial 5' untranslated regions for nucleic acid expression
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
WO2005039504A2 (en) 2003-10-24 2005-05-06 Eisai Co., Ltd. Compounds and methods for treating toll-like receptor 2-related diseases and conditions
US20050153333A1 (en) 2003-12-02 2005-07-14 Sooknanan Roy R. Selective terminal tagging of nucleic acids
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
EP1547581A1 (en) 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
WO2005070456A2 (en) 2004-01-09 2005-08-04 Millennium Pharmaceuticals, Inc. Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
WO2005066337A2 (en) 2004-01-09 2005-07-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation
WO2005076979A2 (en) 2004-02-06 2005-08-25 Wyeth Diagnosis and therapeutics for cancer
US7666583B2 (en) 2004-02-19 2010-02-23 Yale University Identification of cancer protein biomarkers using proteomic techniques
AU2005215943A1 (en) 2004-03-01 2005-09-09 Peptera Pharmaceutical Ltd. Casein derived peptides and therapeutic uses thereof
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7553944B2 (en) 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
WO2006026569A2 (en) 2004-08-27 2006-03-09 Northeastern University Comprehensive characterization of complex proteins at trace levels
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
WO2006027202A1 (en) 2004-09-06 2006-03-16 Unite De Recherche En Biotherapie Et Oncologie (Rubio) Generation of multiparent cell hybrids
AU2005282241B2 (en) 2004-09-08 2011-03-03 Chelsea Therapeutics, Inc. Quinazoline derivatives as metabolically inert antifolate compounds.
US8247371B2 (en) 2004-10-14 2012-08-21 Yale University Therapy with Clostridium perfringens enterotoxin to treat ovarian and uterine cancer
HUE026826T2 (en) 2004-10-29 2016-07-28 Ratiopharm Gmbh Modeling and glycopegylation of fibroblast growth factor (FGF)
US7429567B2 (en) 2005-01-04 2008-09-30 The Brigham And Women's Hospital, Inc. Sustained delivery of PDGF using self-assembling peptide nanofibers
CN101133037B (zh) 2005-01-27 2012-05-09 旭化成制药株式会社 六元杂环化合物及其用途
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
BRPI0607323B8 (pt) 2005-02-14 2021-05-25 Epitopix Llc composições, usos de polipeptídeos e de anticorpos, bem como kits para a detecção de anticorpo que se liga especificamente a um polipeptídeo
KR20080003321A (ko) 2005-02-24 2008-01-07 세미네스 인코퍼레이티드 생물학적 샘플을 분류하는 조성물 및 방법
US8551774B2 (en) 2005-03-17 2013-10-08 National Research Council Of Canada Expression vectors containing a truncated epstein barr nuclear antigen 1 lacking the Gly-Gly-Ala domain for enhanced transient gene expression
WO2006102097A2 (en) 2005-03-17 2006-09-28 President And Fellows Of Harvard College Synthesis of avrainvillamide, stephacidin b, and analogues thereof
FR2885525B1 (fr) 2005-05-13 2009-09-18 Urodelia Sa Medicament notamment anti-cancereux, destine a des traitements par immunotherapie, en particulier autologue
WO2006138238A2 (en) 2005-06-13 2006-12-28 Cleveland Biolabs, Inc. Methods of protecting against apoptosis using lipopeptides
WO2006138380A2 (en) 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
MX2008000141A (es) 2005-06-27 2008-04-07 Exelixis Inc Moduladores de lxr basados en imidazol.
WO2007005249A2 (en) 2005-06-29 2007-01-11 Hyperbranch Medical Technology, Inc. Nanoparticles and dendritic-polymer-based hydrogels comprising them
US7494788B2 (en) 2005-07-11 2009-02-24 Molecular Kinetics, Inc. Entropic bristle domain sequences and their use in recombinant protein production
US7820790B2 (en) 2005-07-13 2010-10-26 Amgen Mountain View Inc. IL-6 binding proteins
EP1904649A2 (en) 2005-07-18 2008-04-02 Epigenomics AG Compositions and methods for cancer diagnostics comprising pan-cancer markers
GB0516058D0 (en) 2005-08-04 2005-09-14 Oxford Genome Sciences Uk Ltd New protein isoforms and uses thereof
GB0517293D0 (en) 2005-08-24 2005-10-05 Cancer Rec Tech Ltd Vectors and uses thereof
DE602006014846D1 (de) 2005-09-15 2010-07-22 Alk Abello As Verfahren zur quantifizierung von allergenen
WO2007044804A2 (en) 2005-10-11 2007-04-19 Chemocentryx, Inc. Piperidine derivatives and methods of use
AU2006303037A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
ATE486875T1 (de) 2005-11-10 2010-11-15 Chemocentryx Inc Substituierte chinolone und verwendungsverfahren
EP1954134B1 (en) 2005-11-23 2011-09-14 Merck Sharp & Dohme Corp. Process for synthesizing a 2-phenyl-1h-phenantrho[9,10-d]imidazole derivative
KR101049859B1 (ko) 2007-11-28 2011-07-19 대한민국 Ｎ-말단 ｐＩ 값 조절에 의한 수용성 재조합 단백질 생산방법
KR20080113223A (ko) 2006-03-06 2008-12-29 심포젠 에이/에스 호흡기세포 융합 바이러스 감염 치료용 재조합 폴리클로날 항체
JP5167155B2 (ja) 2006-03-09 2013-03-21 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法
EP1996629A2 (en) 2006-03-10 2008-12-03 Warwick Effect Polymers Ltd. Polymers
WO2007110755A1 (en) 2006-03-27 2007-10-04 Medical Therapies Limited Prophylaxis or treatment of cardiovascular inflammation
CA2649800C (en) 2006-04-20 2016-09-20 Kringle Pharma Inc. Hgf precursor protein variant and active protein thereof
US20090253156A1 (en) 2006-05-05 2009-10-08 Perkinelmer Las, Inc. Mass spectrometry methods for multiplexed quantification of protein kinases and phosphatases
EP2021467A4 (en) 2006-05-08 2010-01-20 Adaerata Ltd Partnership CHIMERIC PCSK9 PROTEINS, THESE INCLUDING CELLS AND TEST METHODS THEREWITH
EP2502628B1 (en) 2006-06-23 2016-12-14 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
US20120128661A1 (en) 2006-06-23 2012-05-24 Alethia Biotherapeutics Inc. Polynucleotide and polypeptide sequences involved in cancer
EP2041556A1 (en) 2006-06-28 2009-04-01 RGB Technologies AB A sensor kit and a system for detecting an analyte in a test environment
US8198046B2 (en) 2006-07-11 2012-06-12 Danisco Us Inc. KEX2 cleavage regions of recombinant fusion proteins
US20080248959A1 (en) 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
EP2121747A2 (en) 2006-07-27 2009-11-25 Oxford Genome Sciences (UK) Limited New protein isoforms and uses thereof
US20100120627A1 (en) 2006-08-02 2010-05-13 Abdelmajid Belouchi Genemap of the human genes associated with psoriasis
JP5244103B2 (ja) 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法
US8314221B2 (en) 2006-09-07 2012-11-20 Laurence Claude Faure Pharmacodiagnostic test targeting oncology and neurodegeneration
WO2008033932A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biarylthiazole carboxylic acid derivatives as protein tyrosine phosphatase-ib inhibitors
CN101663308A (zh) 2006-10-30 2010-03-03 桑尔克斯药品公司 N-甲基色胺钙五水合物(dcp)和基于它的治疗方法
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
US20100150950A1 (en) 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
CA2672860C (en) 2006-12-28 2013-01-29 Abbott Laboratories Inhibitors of poly(adp-ribose)polymerase
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
KR101493474B1 (ko) 2007-01-09 2015-02-16 클리브랜드 바이오랩스, 아이엔씨. 조혈 줄기 세포를 증가시키고 이동시키는 방법들
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
US20080311145A1 (en) 2007-04-04 2008-12-18 Specigen, Inc. Protein cage immunotherapeutics
WO2009009186A2 (en) 2007-04-13 2009-01-15 The Regents Of The University Of California Receptors useful for gas phase chemical sensing
US20080306007A1 (en) 2007-04-30 2008-12-11 Newcastle Innovation Limited Agents for prophylaxis or treatment of neurological related diseases and conditions
WO2008134761A2 (en) 2007-04-30 2008-11-06 Intezyne Technologies, Inc. Modification of biological targeting groups for the treatment of cancer
US8143372B2 (en) 2007-05-21 2012-03-27 Children's Hospital & Research Center Oakland Synthetic regulators of ferritin protein nanocage pores and methods of use thereof
US20090176664A1 (en) 2007-06-01 2009-07-09 Keting Chu High density peptide arrays containing kinase or phosphatase substrates
US8618121B2 (en) 2007-07-02 2013-12-31 Cancer Research Technology Limited 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
US9018138B2 (en) 2007-08-16 2015-04-28 The Johns Hopkins University Compositions and methods for generating and screening adenoviral libraries
CN101821289A (zh) 2007-09-07 2010-09-01 西福根有限公司 重组制造抗rsv抗体的方法
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
DK2538222T3 (da) 2007-11-05 2021-11-15 Nordic Bioscience As Biokemiske markører til cvd-risikovurdering
US20100298368A1 (en) 2007-11-06 2010-11-25 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
EP2071334A1 (en) 2007-12-14 2009-06-17 Transmedi SA Compositions and methods of detecting TIABS
WO2009111088A2 (en) 2008-01-02 2009-09-11 The Johns Hopkins University Antitumor immunization by liposomal delivery of vaccine to the spleen
US8568709B2 (en) 2008-03-20 2013-10-29 University Health Network Thymidylate kinase fusions and uses thereof
WO2009134370A2 (en) 2008-04-30 2009-11-05 University Of Vermont And State Agricultural College Methods and products relating to gsk3 beta regulation
JP5777510B2 (ja) 2008-05-09 2015-09-09 エボニック コーポレイションＥｖｏｎｉｋ Ｃｏｒｐｏｒａｔｉｏｎ 生物適合性及び生分解性のエラストマー性ポリマー
US20110123637A1 (en) 2008-05-26 2011-05-26 Universitat Zurich Protamine/rna nanoparticles for immunostimulation
PE20100094A1 (es) 2008-07-03 2010-02-18 Amira Pharmaceuticals Inc Antagonistas heteroalquilo de receptores de prostaglandina d2
US8148088B2 (en) 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
WO2010014141A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
ES2415234T3 (es) 2008-08-08 2013-07-24 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad Hsp90
MX2011003117A (es) 2008-09-19 2011-04-21 Nektar Therapeutics Conjugados polimericos de peptidos terapeuticos.
WO2010033220A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2010060186A1 (en) 2008-11-03 2010-06-03 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
RU2562865C2 (ru) 2009-07-10 2015-09-10 Иннэйт Фарма Tlr3 связывающие агенты
ES2546410T3 (es) 2009-08-06 2015-09-23 John Wayne Cancer Institute Diagnosis de cáncer de mama, y otros tipos de cáncer, de tipo basal primario y metastásico
WO2011054112A1 (en) 2009-11-03 2011-05-12 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of kidney associated antigen 1
JP2013522237A (ja) 2010-03-11 2013-06-13 メリマック ファーマシューティカルズ インコーポレーティッド トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用
DK3173427T3 (da) 2011-03-31 2019-08-05 Adc Therapeutics Sa Antistoffer mod nyre-associeret antigen 1 og antigen-bindende fragmenter deraf
HRP20190946T1 (hr) 2012-01-09 2019-07-26 Adc Therapeutics Sa Sredstva za liječenje trostruko negativnog raka dojke

Also Published As

Publication number Publication date
EP3130674A1 (en) 2017-02-15
US20180369269A1 (en) 2018-12-27
MX2011004684A (es) 2011-10-06
US20120093819A1 (en) 2012-04-19
CA2740900C (en) 2019-09-24
EP3130674B1 (en) 2020-07-08
WO2010060186A1 (en) 2010-06-03
JP2015142592A (ja) 2015-08-06
MX336869B (es) 2016-02-04
ZA201104110B (en) 2016-01-27
BRPI0921805A2 (pt) 2016-11-01
EP2362908A4 (en) 2013-09-18
US20110223107A1 (en) 2011-09-15
CA2740900A1 (en) 2010-06-03
AU2009321508A1 (en) 2010-06-03
CN104829714A (zh) 2015-08-12
WO2010060186A8 (en) 2011-06-09
US9855291B2 (en) 2018-01-02
CN102245773B (zh) 2014-08-27
JP2012507266A (ja) 2012-03-29
KR20110084280A (ko) 2011-07-21
IL212637A0 (en) 2011-07-31
US8580257B2 (en) 2013-11-12
CA3050455A1 (en) 2010-06-03
CN102245773A (zh) 2011-11-16
JP5781932B2 (ja) 2015-09-24
EP2362908A1 (en) 2011-09-07
AU2009321508B2 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
CY1121208T1 (el) Σκευασματα αντισωματος ναταλιζουμαμπης
MY161909A (en) Anti-her3 antibodies and uses thereof
AU2009260320A8 (en) Antibodies to IL-6 and their uses
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
GB201020995D0 (en) Biological materials and uses thereof
MX375439B (es) Moleculas de union cd37 y sus inmunoconjugados.
AU2012328921A8 (en) Immunobinders directed against TNF
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
MX2009004167A (es) Anticuerpos que enlazan epitopos cxcr7.
TN2010000213A1 (en) Wise binding antibodies and epitopes
MY156315A (en) Anti-vegf antibodies
WO2010100056A3 (en) Antibodies against a proliferating inducing ligand (april)
MY150400A (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
WO2012019024A3 (en) Her3-binding molecules and immunoconjugates thereof
MX339015B (es) Anticuerpos que se fijan a tweak.
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2009026117A3 (en) Novel compounds
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
WO2010064012A3 (en) Treatment of autoimmune disease by modulating annexin-i (lipocortin 1 )
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
MX2010001237A (es) Nuevos anticuerpos.
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток

Legal Events

Date Code Title Description
S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
PSEA Patent sealed
S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 03 NOV 2016 BY FB RICE

Effective date: 20131011

ASS Change of ownership

Owner name: ALETHIA BIOTHERAPEUTICS INC., CA

Effective date: 20131031

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2017 BY FB RICE

Effective date: 20161024

ASS Change of ownership

Owner name: ADC THERAPEUTICS SA, CH

Effective date: 20170724

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2018 BY FB RICE PTY LTD

Effective date: 20171018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2019 BY FB RICE PTY LTD

Effective date: 20181003

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2020 BY FB RICE PTY LTD

Effective date: 20191004

LECA Licensee/mortgages/financial interest

Name of requester: DEERFIELD PARTNERS, L.P.

Effective date: 20200715

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2021 BY FB RICE PTY LTD

Effective date: 20200925

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2022 BY FB RICE PTY LTD

Effective date: 20211006

LAPS Patent lapsed